Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pinacidil Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 known ✓ | O60706 | 9/20 | 0.53 |
| ▸ | KCNJ11 known ✓ | Q14654 | 9/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ABCC8 | Q09428 | 3/20 | 0.36 |
| ▸ | KCNJ8 | Q15842 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pinacidil Anhydrous SCHEMBL65786 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL8478960 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL9275522 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL5051662 | 1.00 | ABCC9 (0.53) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL7061536 | 0.92 | ABCC9 (0.46) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9298624 | 0.84 | KIF11 (0.54) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL11158589 | 0.80 | ABCC9 (0.48) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL8141227 | 0.78 | KCNJ11 (0.39) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL24872316 | 0.77 | CYP3A4 (0.44) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL11164606 | 0.76 | CYP3A4 (0.41) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5196416-A | Percutaneous absorption | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | claimed |
| EP-0306192-B1 | PERMEATION ENHANCEMENT COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| EP-2894149-B1 | Cyanoguanidine prodrugs | LEO PHARMA AS (DK) | 2017-08-02 | — | — | EP | disclosed |
| EP-1838696-B1 | NOVEL CYANOGUANIDINE COMPOUNDS | LEO PHARMA AS (DK) | 2016-03-09 | — | — | EP | disclosed |
| EP-1339686-B1 | CYANOGUANIDINE PRODRUGS | LEO PHARMA AS (DK) | 2015-09-16 | — | — | EP | disclosed |
| EP-2894149-A1 | Cyanoguanidine prodrugs | LEO PHARMA A/S (DK) | 2015-07-15 | — | — | EP | disclosed |
| EP-2838545-A1 | COMPOSITION COMPRISING HERBS | Moleac Pte Ltd. (SG) | 2015-02-25 | — | — | EP | disclosed |
| US-8859594-B2 | Polymorphs of N-(6-(4-chlorophenoxy)hexyl)-N′-cyano-N″-(4-pyridyl)guanidine, and preparation thereof and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2014-10-14 | — | — | US | disclosed |
| US-20130281494-A1 | POLYMORPHS OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N\"-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREOF AND USE THEREOF | TIANJIN MICHELE SCI-TECH DEVELOPMENT CO., LTD. (CN) | 2013-10-24 | — | — | US | disclosed |
| WO-2013141818-A1 | COMPOSITION COMPRISING HERBS | MOLEAC PTE LTD (SG) | 2013-09-26 | — | — | WO | disclosed |
| EP-2634173-A1 | POLYMORPH OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N''-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREFOR AND USE THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-5430048-A | Spirocyclic benzopyran imidazolines | THE UPJOHN COMPANY (US) | 1995-07-04 | — | — | US | disclosed |
| WO-1995017387-A1 | A NOVEL PROCESS FOR PREPARING N''-CYANO-N'-(4-PYRIDYL)-N-(1,2,2-TRIMETHYLPROPYL)-GUANIDINE | EGIS Gyógyszergyár Rt. (HU) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017387-A1 | A NOVEL PROCESS FOR PREPARING N''-CYANO-N'-(4-PYRIDYL)-N-(1,2,2-TRIMETHYLPROPYL)-GUANIDINE | EGIS Gyógyszergyár Rt. (HU) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995017387-A1 | A NOVEL PROCESS FOR PREPARING N''-CYANO-N'-(4-PYRIDYL)-N-(1,2,2-TRIMETHYLPROPYL)-GUANIDINE | EGIS Gyógyszergyár Rt. (HU) | 1995-06-29 | — | — | WO | disclosed |
| US-5380734-A | N-cyanoamidine derivatives as anti-influenza agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-01-10 | — | — | US | disclosed |
| US-5256668-A | Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| EP-0559411-A1 | Titratable transdermal patch system and method for administration of therapeutic substances | ELI LILLY AND COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5196416-A | Percutaneous absorption | ELI LILLY AND COMPANY (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0306192-B1 | PERMEATION ENHANCEMENT COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1992-05-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281494-A1 | POLYMORPHS OF N-(6-(4-CHLOROPHENOXY)HEXYL)-N'-CYANO-N\"-(4-PYRIDYL)GUANIDINE, AND PREPARATION THEREOF AND USE THEREOF | PNP, HCCS, UNG | ABCC9 1574/4885KCNJ11 4001/4885CYP3A4 232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.